BLTE insider ownership: who sold, why, and what they still hold

What stands out

Hendrik Scholl sold $2.9M of stock with no disclosed trading plan. The filings don't state a reason.Largest such sale, Jun 18, 2026

Selling picked up in the last 90 days: officers and directors sold 169K shares, against an average of 39K per 90 days earlier in the period. Most of it was Yu-Hsin Lin (101K shares in the last 90 days) and Hao-Yuan Chuang (68K shares in the last 90 days); 100% of these sales were under disclosed plans.Yu-Hsin Lin: largest recent sale, Sep 4, 2026 · Hao-Yuan Chuang: largest recent sale, Sep 4, 2026

A share of stake is shown for 0 of the 5 officers and directors who sold. 9 are left out

Left out: Yu-Hsin Lin, Hao-Yuan Chuang, Hendrik Scholl, Wan-Shan Chen, Nathan Mata, Xiao-Hui Chen, Gary Biddle, Ita Lu and John Longo (share of stake is being verified).

Disclosed company stock is not an insider's whole wealth.

Who sold, and how much of their stake

Officers and directors, since March 18, 2026. Their share of stake is being verified and is not shown yet; amounts and trading plans are below.

Yu-Hsin Lin

Chief Executive Officer, Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$20.8MDisclosed plan

Hao-Yuan Chuang

Chief Financial Officer, Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$14.0MDisclosed plan

Hendrik Scholl

Chief Medical Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$2.9M3% planned 97% no plan disclosed

Nathan Mata

Chief Scientific Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$2.7MDisclosed plan

Wan-Shan Chen

Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$198KDisclosed plan

Amounts, filings and trading plans for each seller

Selling by month

Officers and directors, Mar 2026 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planNo plan disclosedOne dollar scale for every month; the tallest bar is labeled

Recent activity

Past 30 days, Sep 17, 2026 to Oct 16, 2026

Oct 1, 2026Hendrik Scholl sold 500 shares ($83K) under a disclosed trading plan.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Hendrik Scholl Chief Medical Officer	500	$165.32	n/a	n/a	Oct 1, 2026	Oct 5, 2026

"% of total stake" is the shares in an event against all the vested shares the person held that day, across every share class and holding entity, after that day's vesting. "n/a" means the person's holdings are not confirmed, or the row is a purchase. "Holdings record incomplete" means more shares were sold than the filings show the person held that day, so a percentage would be wrong.

Common questions

Is the Belite Bio, Inc CEO selling stock?

Yes. Yu-Hsin Lin sold 110K shares ($20.8M) since March 18, 2026, all of it under a trading plan disclosed in the filings.

Why are Belite Bio, Inc insiders selling?

Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 93% of sales by value ran under 10b5-1 trading plans disclosed in the filings and 7% had no disclosed plan. A trading plan schedules sales in advance.

Are any Belite Bio, Inc insiders buying?

No. Officers and directors reported no purchases since March 18, 2026.

The evidence

Who sold5 officers and directors: amount, % of holdings, trading plan

Who sold	Amount	% of holdings	Trading plan
Yu-Hsin Lin Chief Executive Officer, Director	$20.8M 110K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Hao-Yuan Chuang Chief Financial Officer, Director	$14.0M 74K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Hendrik Scholl Chief Medical Officer	$2.9M 21K shares	Not confirmed share of stake is being verified. Why	3% under a disclosed plan 97% no plan disclosed
Nathan Mata Chief Scientific Officer	$2.7M 17K shares	Not confirmed share of stake is being verified. Why	Disclosed plan
Wan-Shan Chen Director	$198K 1.1K shares	Not confirmed share of stake is being verified. Why	Disclosed plan

The full ownership picture0 of 9 officers and directors confirmed

Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.

Insider

Held Mar 17, 2026

Sold

Held Oct 16, 2026

Still held

Yu-Hsin Lin

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Yu-Hsin Lin are complete.

Chief Executive Officer, Director

n/a

−110K

n/a

Vesting, gifts, unvested awards and holding lines for Yu-Hsin Lin

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Yu-Hsin Lin are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
413,908	$0.44	Dec 22, 2030	$70.2M
27,778	$6.00	Apr 17, 2032	$4.6M
166,667	$14.45	Jul 16, 2033	$25.9M
208,334	$48.46	Aug 28, 2034	$25.3M
200,000	$54.88	Feb 11, 2035	$23.0M
40,000	$77.40	Oct 6, 2035	$3.7M
80,000	$93.02	Oct 27, 2035	$6.2M
150,000	$158.36	Jan 8, 2036	$1.7M

Estimate: options held × ($170.02 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Hao-Yuan Chuang

Chief Financial Officer, Director

n/a

−74K

n/a

Vesting, gifts, unvested awards and holding lines for Hao-Yuan Chuang

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Hao-Yuan Chuang are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
289,736	$0.44	Dec 22, 2030	$49.1M
26,112	$6.00	Apr 17, 2032	$4.3M
120,834	$14.45	Jul 16, 2033	$18.8M
250,000	$48.46	Aug 28, 2034	$30.4M
200,000	$54.88	Feb 11, 2035	$23.0M
40,000	$77.40	Oct 6, 2035	$3.7M
80,000	$93.02	Oct 27, 2035	$6.2M
150,000	$158.36	Jan 8, 2036	$1.7M

Estimate: options held × ($170.02 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Hendrik Scholl

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. See the filing Sales and other transactions for Hendrik Scholl are complete.

Chief Medical Officer

n/a

−21K

n/a

Vesting, gifts, unvested awards and holding lines for Hendrik Scholl

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Hendrik Scholl are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
100,000	$48.68	Aug 31, 2034	$12.1M
75,000	$54.88	Feb 11, 2035	$8.6M
40,000	$158.36	Jan 8, 2036	$466K
10,000	$77.40	Oct 6, 2035	$926K

Estimate: options held × ($170.02 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Wan-Shan Chen

Director

n/a

−1.1K

n/a

Vesting, gifts, unvested awards and holding lines for Wan-Shan Chen

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Wan-Shan Chen are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
13,796	$0.44	Dec 22, 2030	$2.3M

Estimate: options held × ($170.02 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Nathan Mata

Chief Scientific Officer

n/a

−17K

n/a

Vesting, gifts, unvested awards and holding lines for Nathan Mata

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Nathan Mata are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
267,934	$6.00	Apr 17, 2032	$43.9M
100,000	$14.45	Jul 16, 2033	$15.6M
100,000	$48.46	Aug 28, 2034	$12.2M

Estimate: options held × ($170.02 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Xiao-Hui Chen

Director

n/a

Vesting, gifts, unvested awards and holding lines for Xiao-Hui Chen

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Xiao-Hui Chen are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Gary Biddle

Director

n/a

Vesting, gifts, unvested awards and holding lines for Gary Biddle

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Gary Biddle are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
50,000	$6.00	Apr 17, 2032	$8.2M
60,000	$58.88	Apr 14, 2035	$6.7M

Estimate: options held × ($170.02 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Ita Lu

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Ita Lu are complete.

Director

n/a

Vesting, gifts, unvested awards and holding lines for Ita Lu

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Ita Lu are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
50,000	$14.45	Jul 16, 2033	$7.8M
60,000	$58.88	Apr 14, 2035	$6.7M

Estimate: options held × ($170.02 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

John Longo

Director

n/a

Vesting, gifts, unvested awards and holding lines for John Longo

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for John Longo are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
50,000	$6.00	Apr 17, 2032	$8.2M
60,000	$58.88	Apr 14, 2035	$6.7M

Estimate: options held × ($170.02 − strike price), using the most recent insider trade price on Form 4 (Oct 1, 2026), not a market close.

Holdings and share of stake for Belite Bio, Inc are being verified, so no balances, unit counts or percentages are shown. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings.

What explains the selling$40.6M of sales by plan status, purpose, seller and month

Officer and director open-market sales: $40.6M across 222,228 shares. Plan status and stated purpose are separate questions, and a sale can have both.

By plan status

Disclosed plan · $37.8M · 93%

The lighter segment is sales with no plan disclosed in the filing ($2.9M), including tax-related sales outside a plan.

No plan disclosed · $2.9M

Sales with no 10b5-1 plan and no tax reference in the filing. $2.9M of it is Hendrik Scholl. No plan disclosed is a statement about the filing, not about why the sale happened. Largest such sale: Hendrik Scholl, Jun 18, 2026

Seller	Shares sold	Proceeds	Under a disclosed plan	Share of total	Sales dates
Yu-Hsin Lin Chief Executive Officer, Director	110K	$20.8M	100%	51%	Apr 9, 2026 to Sep 8, 2026
Hao-Yuan Chuang Chief Financial Officer, Director	74K	$14.0M	100%	34%	Apr 9, 2026 to Sep 8, 2026
Hendrik Scholl Chief Medical Officer	21K	$2.9M	3%	7%	Jun 16, 2026 to Oct 1, 2026
Nathan Mata Chief Scientific Officer	17K	$2.7M	100%	7%	Apr 15, 2026 to May 7, 2026
Wan-Shan Chen Director	1.1K	$198K	100%	0.5%	Apr 9, 2026 to Apr 9, 2026

Sales by month

Month	Sale proceeds	Disclosed plan	To cover taxes	No plan disclosed
Mar 2026	$0	$0	$0	$0
Apr 2026	$4.9M	$4.9M	$0	$0
May 2026	$723K	$723K	$0	$0
Jun 2026	$2.9M	$0	$0	$2.9M
Jul 2026	$0	$0	$0	$0
Aug 2026	$132K	$132K	$0	$0
Sep 2026	$31.9M	$31.9M	$0	$0
Oct 2026	$83K	$83K	$0	$0

Known gaps and uncertainty9 officers and directors not confirmed

Holdings and share of stake are being verified. Balances, unit counts and every share-of-stake figure for Belite Bio, Inc are held back until that check is finished. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings and are complete.

External context: we only cite outside events when a documented connection exists. None is shown for this period.

Sources and methodology43 filings on record, 43 filed since March 18, 2026, and how we read them

All 43 Forms 3, 4 and 5 on record for Belite Bio, Inc (SEC CIK 1889109), filed from Mar 18, 2026 to Oct 5, 2026; 43 of them were filed in the 12 months this page covers, retrieved from SEC EDGAR on Oct 16, 2026. Prices are the ones reported in each filing, often weighted averages.

Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.

Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".

Full methodology

Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.

Belite Bio, Inc insiders sold $40.6M since March 18, 2026. How much of their stake is that?

What stands out

Who sold, and how much of their stake

Selling by month

Recent activity

Common questions

Is the Belite Bio, Inc CEO selling stock?

Why are Belite Bio, Inc insiders selling?

Are any Belite Bio, Inc insiders buying?

The evidence

No plan disclosed · $2.9M

Sales by month